glp-1 and medicare CMS Issues Coverage Guidance on Anti-Obesity Drugs The Medicare GLP-1 Bridge Begins
Description
These are well established and each trial that you read where a GLP-1 is studied, alone or in combination with another incretin, you will find the first 4 adverse effects as the most common
Variants in GLP1R (the GLP-1 receptor itself), GIPR (rs1800437 is the headline variant for differential GLP-1 response), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) are associated with measurably different response patterns to semaglutide and tirzepatide
Im all for hype
Understanding the precise mechanisms of these benefits and whether they extend to non-diabetic populations remains a critical area of research
Structure of glucagon-like peptide(7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR
